MedTrace Logo

Remimazolam Tosilate Sedation and Midazolam Sedation in Dental Patients

NCT04602845 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2022-03-15

No results posted yet for this study

Summary

Remimazolam Tosilate is a new short-acting benzodiazepines used in sedation. It has the advantages of rapid metabolism, quick recovery without injection pain. This study aims to compared with Midazolam, study whether Remimazolam Tosilate can achieve the same sedation effect with lower side effects on sedation maintenance period, During the recovery period of anesthesia, can Remimazolam Tosilatebe more stable and rapid.

Conditions

  • Sedation Complication
  • Midazolam
  • Remimazolam

Interventions

DRUG

Fentanyl

50ug Fentanyl intravenously

DRUG

Flurbiprofen

50mg Fentanyl intravenously

DRUG

Midazolam

2.5mg midazolam in 2ml normal saline intravenously

DRUG

Remimazolam

3mg Remimazolam in 2ml normal saline intravenously

Sponsors & Collaborators

  • Peking University

    lead OTHER

Principal Investigators

  • Xudong Yang, MD · Department of anesthesiology of peking university school of stomatology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2021-06-30
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04602845 on ClinicalTrials.gov